---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-008313"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:39:46.560351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports FY2022 net loss $11.9M, cash runway into Q3 2023; clinical milestones ahead

## Summary
- Net loss $11.9M in 2022 vs $12.6M in 2021; revenue $1.4M up from $1.0M.
- Cash $7.4M at year-end provides runway into Q3 2023.
- CardiAMP Phase III heart failure trial enrolled 119 patients; DSMB cleared, adaptive SAP submitted.
- NK1R+ MSC allogeneic trial for HFrEF (BCDA-03) IND approved; first patient expected Q2 2023.
- Japan submission for CardiAMP approval planned for Q2 2023.

## SEC filing metadata
- accession: 0001437749-23-008313
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/0001437749-23-008313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/bcda20230328_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-008313
- JSON: https://secwatch.observer/filing/0001437749-23-008313.json
- Plain text: https://secwatch.observer/filing/0001437749-23-008313.txt

## Key facts
- Earnings Releases
  BioCardia, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/0001437749-23-008313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.